𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Head and neck cancer: Response to p53-based therapeutics

✍ Scribed by Jackie Nemunaitis; John Nemunaitis

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
97 KB
Volume
33
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Limited options are available for patients with advanced stage head and neck cancer. The p53 gene is known as the β€œguardian of the genome.” Mutations of the p53 gene predispose to carcinogenesis. The p53 mutations are common in head and neck cancer. Replacement of p53 gene function in preclinical models demonstrates cancer regression and improved survival. Clinical data with an adenoviral based p53 gene delivery product (Advexin) supports safety and clinical response after direct intratumoral injection. We summarize p53‐related therapeutics in this review. Β© 2010 Wiley Periodicals, Inc. Head Neck, 2011

πŸ“œ SIMILAR VOLUMES

Overexpression of P53 in head and neck c
Overexpression of P53 in head and neck cancer
✍ David L. Watling; Dr. Allen M. Gown; Dr. Marc D. Coltrera πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 766 KB

The putative tumor suppressor gene p53 plays a key role in the regulation of cell proliferation. Functional loss of p53 protein through mutation or viral oncogene-complexing can result in p53 protein overexpression detectable by immunocytochemistry, which in turn has been associated with markers of

Cell-mediated immune response in head an
Cell-mediated immune response in head and neck cancer patients
✍ Dr. A. Olivari; R. Pradier; J. Feierstein; A. Guardo; H. Glait; A. Rojas πŸ“‚ Article πŸ“… 1976 πŸ› John Wiley and Sons 🌐 English βš– 381 KB

## Abstract The immune reactivity of 100 head and neck cancer patients was studied by means of DNCB, candidine, blastic transformation with PHA, and lymphocyte counts. DNCB reactivity was strong in only 21% of the population and was found impaired in patients with advanced primitive tumors, with m